What is BioMarin Pharmaceutical's (bmrn) stock price potential upside?
On average, they expect BioMarin Pharmaceutical's stock price to reach $112.57 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
Where can I buy shares of bmrn?
Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Does BioMarin Pharmaceutical stock pay a dividend?
BioMarin Pharmaceutical does not currently pay a dividend. BioMarin Pharmaceutical does not have a long track record of dividend growth. In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought.
Is Bmrn stock a buy?
BioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Why is Bmrn stock down?
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
Is BioMarin a public company?
BioMarin Pharmaceutical (NASDAQ:BMRN shareholders incur further losses as stock declines 4.9% this week, taking five-year losses to 14%
Is BioMarin a takeover target?
Both BioMarin and Incyte (see below) also have been mentioned by Zacks Investment Research as attractive acquisition targets. Additionally, The Wall Street Journal notes that slowing revenue growth in Big Pharma creates a major impetus for M&A activity.
What is BioMarin known for?
Pioneers in Rare Disease Established in 1997, BioMarin is a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases.
Is BioMarin a biotech company?
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
Who owns BioMarin pharmaceuticals?
Jean-Jacques BienaiméBioMarin PharmaceuticalTypePublicFoundedMarch 1997FoundersChristopher Starr, Ph.D. Grant W. Denison Jr.HeadquartersSan Rafael, California, U.S.Key peopleJean-Jacques Bienaimé (Chairman & CEO) Daniel Spiegelman (Executive VP & CFO) Brian R. Mueller (Senior VP, Finance & CAO)12 more rows
Is BioMarin a good company?
SAN RAFAEL, Calif., April 17, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's 2018 list.
Should I buy or sell BioMarin Pharmaceutical stock right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are cur...
What is BioMarin Pharmaceutical's stock price forecast for 2022?
13 Wall Street analysts have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $88.00 to $147.00. On a...
How has BioMarin Pharmaceutical's stock price performed in 2022?
BioMarin Pharmaceutical's stock was trading at $88.35 at the beginning of 2022. Since then, BMRN stock has decreased by 15.0% and is now trading at...
When is BioMarin Pharmaceutical's next earnings date?
BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast...
How were BioMarin Pharmaceutical's earnings last quarter?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Wednesday, April, 27th. The biotechnology company reported $0.31 e...
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?
BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share (EPS) guidance of...
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the following people: Mr. Jean-Jacques Bienaime M.B.A. , MBA, Chairman & CEO (Age 69, Pay $3....
What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?
161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com . Jean-Jacques Bienaimé has an approval rating of 94%...
Who are some of BioMarin Pharmaceutical's key competitors?
Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...
About BioMarin Pharmaceutical
BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W.
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, Februa..
14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock.
12 biotech stocks to consider buying now as prospects for the sector brighten this year
SAN RAFAEL, Calif., Feb. 10, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a co...
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe H..
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc
SAN RAFAEL, Calif., Feb. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 ...
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress o..
Wilmington, Delaware-- (Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ:...
BioMarin CEO: There are biotech companies 'that probably should not be on the market today'
SAN RAFAEL, Calif., Feb. 2, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company will be presenting data in several presentations on valoctocogene roxaparvov...
BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'
BioMarin CEO JJ Bienaimé joins Yahoo Finance Live's Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biote...
Does market cap include convertible securities?
Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.
Does BioMarin sell PKU?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
